Atara Biotherapeutics

Ebvallo CHMP Opinion and EU Approval

In a groundbreaking achievement, Atara Biotherapeutics secured approval for Ebvallo, the first-ever approved allogeneic cell therapy.

In the build-up to this milestone approval I played a leading role in developing and executing our comprehensive project strategy, for both a positive CHMP opinion, and EU approvel which included:

Corporate Narratives and Messaging
Earned and Social Media Strategies and Deliverables (i.e. press releases,
Social Media Content
Internal Communications

Disclosure: Some materials associated with these efforts contain confidential information and cannot be shown here, but I am happy to elaborate on the framework for them in a live discussion if you have any questions.

Developing the Revamped Corporate Narrative and Approval Messaging

I engaged in Atara’s corporate narrative overhaul and EU approval messaging exercises. My role in these processes included:

Developing process and workback plans
Auditing previous narrative materials to identify areas for improvement
Staffing leadership discovery sessions
Reviewing draft deliverables prior to client delivery
Developing rollout plans for Atara to utilize internally

Earned and Social Media Strategies - CHMP Positive Opinion

I informed development of tactical plans for earned and social media efforts around the EU approval, as well as the CHMP opinion beforehand. I also played a driving role in presenting these strategies to corporate communications leadership at Atara and then moving forward execution. Below, you may see a topline overview of the strategic materials.

Objectives and Approach